Cipla has announced its audited financial results for the quarter and financial year ended 31st March 2026. The company reported a consolidated annual revenue of ₹28,162.59 crore and a net profit of ₹3,861.74 crore. Furthermore, the Board of Directors has recommended a final dividend of ₹13 per equity share for the fiscal year, with a record date set for 5th June 2026.
Financial Performance Summary
For the fiscal year ended 31st March 2026, Cipla achieved a consolidated total revenue of ₹28,162.59 crore, compared to ₹27,547.62 crore in the previous year. The company’s consolidated net profit for the year stood at ₹3,861.74 crore. For the final quarter (Q4: Jan-Mar 2026), the company recorded a consolidated total revenue of ₹6,689.36 crore and a net profit of ₹542.51 crore.
Final Dividend Declaration
Demonstrating its commitment to shareholder value, the Board of Directors has recommended a final dividend of ₹13 per equity share for the financial year ended 31st March 2026. The dividend payout is subject to approval by shareholders at the upcoming Annual General Meeting. The company has designated 5th June 2026 as the record date for determining shareholder eligibility for the dividend payment.
Strategic Developments
During the fiscal year, Cipla completed the acquisition of a 100% stake in Inzpera Healthsciences Limited for ₹110.65 crore. Additionally, the Board has approved a scheme of amalgamation between Cipla Limited and its wholly-owned subsidiary, Inzpera Healthsciences Limited, to streamline operations. The company also reassessed its operating segments, now reporting under a single segment: Pharmaceutical and related products.
Litigation and Operational Updates
The company provided an update on ongoing litigation concerning demand notices from the National Pharmaceutical Pricing Authority (NPPA). The total amount in litigation, after removing duplications, is approximately ₹2,011 crore, consisting of ₹863 crore in principal and ₹1,148 crore in interest. Cipla maintains a favorable legal outlook and has not deemed any specific provision necessary at this time.
Source: BSE
